Advanced search
Publication Cover
Pragmatic and Observational Research Volume 15, 2024 - Issue
Submit an article Journal homepage
15
Views
0
CrossRef citations to date
0
Altmetric
RESPONSE TO LETTER

Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Response to Letter]

Tiago Biachi de Castria1 Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;2 Morsani College of Medicine, University of South Florida, Tampa, FL, USA
&
Richard D Kim1 Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;2 Morsani College of Medicine, University of South Florida, Tampa, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8448-844X
ORCID Icon
Pages 91-92 | Received 24 Jun 2024, Accepted 24 Jun 2024, Published online: 09 Jul 2024

Reference

  • Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.